Press Releases 2017-09-13T20:17:34+00:00

Press Releases

US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics—Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya

Growth of the IL-17 inhibitors and Tremfya has been at the expense of the established TNF inhibitors and Janssen’s own Stelara. Download Report Overview EXTON, Pa., June 12, 2018 /PRNewswire/ — Spherix Global Insights’ second quarter update of RealTime Dynamix™: Psoriasis (US) reveals significant changes afoot in the current psoriasis biologic landscape. Year-over-year analysis indicates continued erosion of the established agents, such as AbbVie’s Humira, Amgen’s Enbrel, and Janssen’s Stelara, in favor of newer biologic entrants with alternate mechanisms of action (MOA). Furthermore, dermatologists’ (n=97) reports of the last five psoriasis biologic/small molecule prescriptions written suggest the declines in tumor [...]

June 12, 2018|

Evolving Treatment Strategies in Multiple Myeloma: Janssen’s Darzalex Leads a Host of Novel Agents in Redefining Treatment Strategies and Approaches

A new independent report from Spherix Global Insights examines the emerging trends and unveils near term shifts that are anticipated in this field which is experiencing its "golden age" of drug development. Download Report Overview EXTON, Pa., June 7, 2018 /PRNewswire/ -- Multiple classes of agents with distinct mechanisms of action are creating new treatment options with more favorable toxicity profiles and improved efficacy and outcomes of combination therapy with existing backbone agents. Based on the recently completed research conducted by Spherix Global Insights with 107 US hematology-oncology specialists, the availability of such a wide range of new classes of [...]

June 7, 2018|

Biosimilars in Nephrology: Pfizer’s Retacrit Gets FDA Clearance and Prepares to Challenge Amgen’s Anemia Franchise Head On

The latest quarterly anemia report from Spherix Global Insights indicates a receptive audience for biosimilar erythropoietin stimulating agents (ESAs), but also a pre-dialysis market looking for ESA-alternatives to anemia management. Download Report Overview EXTON, Pa., May 31, 2018 /PRNewswire/ -- Following the receipt of two Complete Response Letters from the FDA related to manufacturing issues, Pfizer's Retacrit was finally cleared for marketing authorization. Retacrit is the first biosimilar ESA to become available in the US. According to Jay Wish, M.D. Professor of Clinical Medicine at Indiana University and a well-known anemia expert, "The availability of Retacrit in the US is [...]

May 31, 2018|

TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population

According to Spherix Global Insights, data from over 1,000 psoriatic arthritis patients who recently switched therapies reveals that clinical factors, such as joint and skin efficacy, often drive the decision to switch, while non-clinical factors often influence the choice of the new brand. Download Report Overview EXTON, Pa., May 30, 2018 /PRNewswire/ — With four new drug approvals for psoriatic arthritis (PsA) in 2017 (BMS’ Orencia, Eli Lilly’s Taltz, Janssen’s Simponi Aria, and Pfizer’s Xeljanz), the market has become crowded and competitive. In April 2018, Spherix Global Insights collaborated with 214 US rheumatologists to analyze the records of 1,009 patients [...]

May 30, 2018|

Warning to Eli Lilly’s Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat

After a year on the market, Sanofi/Regeneron's Kevzara has had little success overthrowing Roche/Genentech's Actemra as the go-to IL-6 inhibitor for treating rheumatoid arthritis (RA) Download Report Overview EXTON, Pa., May 10, 2018 /PRNewswire/ -- According to Spherix Global Insights' second quarter update of RealTime Dynamix™: Rheumatoid Arthritis (US), at just under one-year post-launch, less than half of US rheumatologists (n=100) have experience prescribing Kevzara to their RA patients. While the percent of respondents prescribing Kevzara in more than five patients has slowly increased and future estimates reveal overall growth of both the user- and patient-base, these projections are not [...]

May 10, 2018|

The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes its Debut with a New Iron Deficiency Anemia Indication in the Pre-Dialysis Setting

According to a recent report published by Spherix Global Insights, about one-third of the surveyed nephrologists (n=202) report the unmet need for new treatments for renal anemia is high. However, other many areas within nephrology, such as diabetic nephropathy and acute kidney injury, are considered a higher priority for new therapeutic options. Download Report Overview EXTON, Pa., May 8, 2018 /PRNewswire/ -- For the past several years, the renal anemia market has been rather sedate, with limited shifting in treatment rates or market share for erythropoietin stimulating agents (ESAs) and IV iron. Changes are percolating, however, in both the dialysis [...]

May 8, 2018|